The trial compared the effectiveness of avastin plus carboplatin and paclitaxel with chemotherapy by carboplatin and paclitaxel alone 试验中用阿瓦斯丁联合卡铂和紫杉醇化疗和单用卡铂和紫杉醇化疗效果进行对比。
The median overall survival time for patients in the avastin plus carboplatin and paclitaxel arm was 12 . 3 months versus 10 . 3 months for patients receiving only carboplatin and paclitaxel 阿瓦斯丁联合卡铂和紫杉醇的平均生存时间为12 . 3个月,与之相对的单用卡铂和紫杉醇的为10 . 3个月。
The most serious adverse events associated with avastin , including some that were fatal , were gastrointestinal perforation , wound healing complications , hemorrhage , blockage of the arteries , abnormally high blood pressure , albumin deficiency in the blood and congestive heart failure 与阿瓦斯丁相关的主要的严重不良反应(包括一些致命性的副作用)是胃肠道穿孔,创口愈合并发症,出血,动脉阻塞,引发性高血压,血液白蛋白降低,出血,心脏病。